What is the current stock price of Surrozen, Inc. (SRZN)?

As of the latest market data, Surrozen, Inc. (SRZN) is trading at $28.20. The stock has seen a gain of 2.73% today.

Does Surrozen, Inc. (SRZN) pay a dividend?

Based on current data, Surrozen, Inc. does not have a confirmed active dividend policy.

What is the market cap of Surrozen, Inc.?

The current market capitalization of Surrozen, Inc. (SRZN) is approximately unavailable.

SRZN

Surrozen, Inc.·Healthcare

28.20

2.732%(+0.75)

Market Closed

30.16

6.950%(+1.96)

After Hours

Last Updated: — ET

52W L: $5.9052W H: $29.99

SRZN NEWS

defenseworld.net

Mar 27

Tcg Crossover Gp Ii, Llc Acquires 106,658 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc acquired 106,658 shares of the firm's stock in a transaction that occurred on Tuesday, March 24th. The shares were bought at an average price of $24.69 per share, with a total value of $2,633,386.02. Following the completion of the purchase, the

globenewswire.com

Mar 23

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Strengthened key leadership roles in 2025 to support long-term ophthalmology strategy SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the fourth quarter and full year 2025 and provided a business update.

defenseworld.net

Mar 18

Tcg Crossover Gp Ii, Llc Purchases 12,374 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc acquired 12,374 shares of the stock in a transaction dated Thursday, March 12th. The stock was acquired at an average price of $24.99 per share, for a total transaction of $309,226.26. Following the completion of the transaction, the insider directly owned

globenewswire.com

Feb 25

Surrozen to Present at Upcoming Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.

globenewswire.com

Feb 23

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of 3,070 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen.

defenseworld.net

Feb 14

Surrozen (NASDAQ:SRZN) & Galmed Pharmaceuticals (NASDAQ:GLMD) Financial Review

Surrozen (NASDAQ: SRZN - Get Free Report) and Galmed Pharmaceuticals (NASDAQ: GLMD - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Institutional and Insider Ownership 66.6% of Surrozen shares

Company Profile

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2021-01-11

Beta

0.52

Websitewww.surrozen.com↗